Anavex Life Sciences Stock Today

AVXL Stock  USD 9.46  0.43  4.76%   

Performance

14 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 6

 
High
 
Low
Low
Anavex Life is selling for 9.46 as of the 29th of November 2024. This is a 4.76% increase since the beginning of the trading day. The stock's lowest day price was 8.88. Anavex Life has only a 6 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. Equity ratings for Anavex Life Sciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of January 2023 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
2nd of August 2006
Category
Healthcare
Classification
Health Care
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company was incorporated in 2004 and is headquartered in New York, New York. The company has 84.8 M outstanding shares of which 18.81 M shares are presently shorted by private and institutional investors with about 13.65 trading days to cover. More on Anavex Life Sciences

Moving together with Anavex Stock

  0.89VTRS ViatrisPairCorr
  0.78ESPR Esperion TherapeuticsPairCorr
  0.83BMY Bristol Myers Squibb Aggressive PushPairCorr

Moving against Anavex Stock

  0.87PFE Pfizer Inc Aggressive PushPairCorr
  0.85LLY Eli Lilly Sell-off TrendPairCorr
  0.83JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.8RDY Dr Reddys LaboratoriesPairCorr
  0.8ZTS Zoetis IncPairCorr
  0.78HLN Haleon plcPairCorr

Anavex Stock Highlights

ESG Sustainability
Environmental
Governance
Social
PresidentStephan Toutain
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities15.1 M14.4 M
Sufficiently Up
Slightly volatile
Total Assets186.4 M177.5 M
Sufficiently Up
Slightly volatile
Total Current Assets186.4 M177.5 M
Sufficiently Up
Slightly volatile
Debt Levels
Anavex Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Anavex Life's financial leverage. It provides some insight into what part of Anavex Life's total assets is financed by creditors.
Liquidity
Anavex Life Sciences currently holds 12.53 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Anavex Life Sciences has a current ratio of 14.65, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Anavex Life's use of debt, we should always consider it together with its cash and equity.

Total Cash From Financing Activities

18.01 Million
Anavex Life Sciences (AVXL) is traded on NASDAQ Exchange in USA. It is located in 630 5th Avenue, New York, NY, United States, 10111 and employs 40 people. Anavex Life is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 765.7 M. Anavex Life Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 84.8 M outstanding shares of which 18.81 M shares are presently shorted by private and institutional investors with about 13.65 trading days to cover. Anavex Life Sciences currently holds about 149.16 M in cash with (27.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Check Anavex Life Probability Of Bankruptcy
Ownership Allocation
Anavex Life holds a total of 84.8 Million outstanding shares. 30% of Anavex Life Sciences outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Anavex Ownership Details

Anavex Stock Institutional Holders

InstituionRecorded OnShares
Oz Management Llc2024-09-30
370.4 K
Nuveen Asset Management, Llc2024-06-30
304.2 K
Bank Of New York Mellon Corp2024-06-30
280.6 K
Susquehanna International Group, Llp2024-06-30
264.4 K
Renaissance Technologies Corp2024-09-30
243.8 K
Jane Street Group Llc2024-06-30
181.9 K
Ubs Group Ag2024-06-30
142.6 K
Rafferty Asset Management, Llc2024-09-30
139.6 K
Exoduspoint Capital Management, Lp2024-09-30
127.3 K
Blackrock Inc2024-06-30
6.4 M
Vanguard Group Inc2024-09-30
4.7 M
View Anavex Life Diagnostics

Anavex Life Historical Income Statement

At this time, Anavex Life's Research Development is quite stable compared to the past year. Non Operating Income Net Other is expected to rise to about 2.9 M this year, although the value of EBIT is projected to rise to (40.6 M). View More Fundamentals

Anavex Stock Against Markets

Anavex Life Corporate Management

CPA CPAPrincipal TreasurerProfile
David RPhSenior AffairsProfile
Juan MDSenior DevelopmentProfile
Dr RPhVP AffairsProfile
Kun JinHead BiostatisticsProfile
Terrie KellmeyerSenior DevelopmentProfile

Already Invested in Anavex Life Sciences?

The danger of trading Anavex Life Sciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anavex Life is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anavex Life. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anavex Life Sciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Anavex Life Sciences is a strong investment it is important to analyze Anavex Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Anavex Life's future performance. For an informed investment choice regarding Anavex Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Return On Assets
(0.20)
Return On Equity
(0.30)
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.